EP4358972A4 - COMPOSITIONS CONTAINING ADENOSINE TRIPHOSPHATE (ATP) AND METHODS OF USE FOR COGNITIVE FUNCTION - Google Patents

COMPOSITIONS CONTAINING ADENOSINE TRIPHOSPHATE (ATP) AND METHODS OF USE FOR COGNITIVE FUNCTION

Info

Publication number
EP4358972A4
EP4358972A4 EP22829221.5A EP22829221A EP4358972A4 EP 4358972 A4 EP4358972 A4 EP 4358972A4 EP 22829221 A EP22829221 A EP 22829221A EP 4358972 A4 EP4358972 A4 EP 4358972A4
Authority
EP
European Patent Office
Prior art keywords
atp
methods
compositions containing
cognitive function
adenosine triphosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22829221.5A
Other languages
German (de)
French (fr)
Other versions
EP4358972A1 (en
Inventor
John Rathmacher
Larry KOLB
Shawn Baier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Usa LLC
Original Assignee
Tsi Usa LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa LLC filed Critical Tsi Usa LLC
Publication of EP4358972A1 publication Critical patent/EP4358972A1/en
Publication of EP4358972A4 publication Critical patent/EP4358972A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP22829221.5A 2021-06-22 2022-06-22 COMPOSITIONS CONTAINING ADENOSINE TRIPHOSPHATE (ATP) AND METHODS OF USE FOR COGNITIVE FUNCTION Pending EP4358972A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (2)

Publication Number Publication Date
EP4358972A1 EP4358972A1 (en) 2024-05-01
EP4358972A4 true EP4358972A4 (en) 2025-04-16

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22829221.5A Pending EP4358972A4 (en) 2021-06-22 2022-06-22 COMPOSITIONS CONTAINING ADENOSINE TRIPHOSPHATE (ATP) AND METHODS OF USE FOR COGNITIVE FUNCTION

Country Status (12)

Country Link
US (1) US20240299435A1 (en)
EP (1) EP4358972A4 (en)
JP (1) JP2024524288A (en)
CN (1) CN117835985A (en)
AU (1) AU2022297444A1 (en)
CA (1) CA3224861A1 (en)
CL (1) CL2023003882A1 (en)
CO (1) CO2024000517A2 (en)
EC (1) ECSP24004256A (en)
MX (1) MX2024000145A (en)
PE (1) PE20241617A1 (en)
WO (1) WO2022271813A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
PH12022550598A1 (en) * 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
BR112022004108A2 (en) * 2019-09-05 2022-05-31 Tsi Group Ltd Methods to enhance the gastrointestinal absorption and systemic utilization of nutritional materials, to increase the bioavailability of a nutritional material in an animal, and to enhance the absorption of a nutritional material in a human

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 7 September 2018 (2018-09-07), ANONYMOUS: "Pre-Workout Boost", XP055791278, retrieved from https://www.gnpd.com/sinatra/recordpage/5950801/ Database accession no. 5950801 *
See also references of WO2022271813A1 *

Also Published As

Publication number Publication date
JP2024524288A (en) 2024-07-05
CN117835985A (en) 2024-04-05
PE20241617A1 (en) 2024-08-07
WO2022271813A1 (en) 2022-12-29
CA3224861A1 (en) 2022-12-29
CO2024000517A2 (en) 2024-05-10
AU2022297444A1 (en) 2024-01-18
CL2023003882A1 (en) 2024-07-05
MX2024000145A (en) 2024-03-22
EP4358972A1 (en) 2024-05-01
ECSP24004256A (en) 2024-02-29
US20240299435A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
EP4329757A4 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP4072576A4 (en) IL-2 ORTHOLOGS AND METHODS OF USE
EP3962296A4 (en) CANNABINOID COMPOSITIONS AND METHODS OF USE
Morita et al. Functional characterization of hematopoietic stem cells in the spleen
EP3968999A4 (en) FGFR INHIBITORS AND METHODS OF USE THEREOF
EP4291193A4 (en) EGFR DEGRADING AGENTS AND METHODS OF USE
EP2061476A4 (en) COMPOSITIONS CONTAINING CDP-CHOLINE AND METHODS OF USE THEREOF
EP4329521A4 (en) COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF
MA30911B1 (en) NOVEL SULFONAMIDE DERIVATIVES AS BRADYKININE ANTAGONISTS
MA31183B1 (en) Mek inhibitors.
EP4035051A4 (en) USE OF SECURE ENCLAVES AND DYNAMIC MEASURES
EP3991733A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPY AGENTS
MA55532A (en) NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
EP4271804A4 (en) METHODS AND COMPOSITIONS FOR THE PREPARATION OF SEQUENCING LIBRARIES
EP4069215A4 (en) TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS FOR THEIR PREPARATION AND USE
EP4358972A4 (en) COMPOSITIONS CONTAINING ADENOSINE TRIPHOSPHATE (ATP) AND METHODS OF USE FOR COGNITIVE FUNCTION
EP4125370A4 (en) PONGAMIA OIL COMPOSITIONS AND THEIR PROCESSES FOR PRODUCTION AND METHODS OF USE
EP3807446A4 (en) SILOXANE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS TO DEPOSIT SILICON-CONTAINING FILMS
EP4211233A4 (en) COMPOSITIONS AND METHODS OF USE THEREOF
EP3969460A4 (en) ASCAROSIDE DERIVATIVES AND METHODS OF USE
EP4031553A4 (en) POLYMERS CONTAINING SUBSTITUTED PHENYLBORONIC ACID AND METHODS OF USE
EP4377314A4 (en) BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING THEM
MA50798A (en) METHODS OF USE AND COMPOSITIONS CONTAINING DULAGLUTIDE
EP4232075A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF SPONDYLODESIS
PL4025579T3 (en) Compositions containing adenosine triphosphate (ATP) and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103878

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250313

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20250310BHEP

Ipc: A61P 25/00 20060101ALI20250310BHEP

Ipc: A61K 31/7076 20060101AFI20250310BHEP